Roche Media News
Media Releases

Roche Media News
  • Roche to present latest oncology advances during ESMO 2014 Congress
    Roche announced today that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain. More than 160 abstracts related to Roche medicines across 15 cancer types have been accepted for presentation during the congress. These presentations include one late-breaking abstract as well as 27 oral presentations, two of which are featured in the congress Presidential Symposia.

  • Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices
    For the sixth consecutive year, Roche has been recognised by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry.

  • Roche's RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)
    Roche announced today that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate (MTX). Treating the disease at this critical early phase may prevent irreversible damage to joints and long-term disability.1,2 RoACTEMRA is the first interleukin-6 (IL-6) receptor antagonist to be approved for use in Europe in patients with early RA.

  • Roche announces change in Board of Directors
    Roche announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico.

  • Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity
    Roche announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets accepting the CE mark. The cobas 6800/8800 Systems offer the fastest time to results with the highest throughput available, along with the longest walk-away time, enabling laboratory staff to drive increased workflow efficiencies, while adapting to their ever-changing testing demands.

  • Roche commences tender offer for InterMune, Inc. for US$74.00 per share in cash
    Roche today announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated 22 August 2014 among Roche Holdings, Inc., Klee Acquisition Corporation, a wholly owned subsidiary of Roche Holdings, Inc., and InterMune, Inc.

  • Roche and InterMune reach definitive merger agreement
    Roche and InterMune, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune’s closing price on 22 August 2014 and a premium of 63% to InterMune’s unaffected closing price on 12 August 2014. The merger agreement has been approved by the boards of InterMune and Roche.

  • Roche Commissions 2014 in Cooperation with the LUCERNE FESTIVAL ACADEMY
    Unsuk Chin's Le Silence des Sirènes will be given its world premiere on 23 August by the LUCERNE FESTIVAL ACADEMY Orchestra and Simon Rattle.

  • FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
    Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.

  • EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer
    Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy.